0002117706-26-000001.txt : 20260326 0002117706-26-000001.hdr.sgml : 20260326 20260325173308 ACCESSION NUMBER: 0002117706-26-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260326 DATE AS OF CHANGE: 20260325 EFFECTIVENESS DATE: 20260326 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pacegenix, Inc. CENTRAL INDEX KEY: 0002117706 ORGANIZATION NAME: EIN: 992817711 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-577711 FILM NUMBER: 26793662 BUSINESS ADDRESS: STREET 1: 245 1ST ST, 18TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6126850244 MAIL ADDRESS: STREET 1: 245 1ST ST, 18TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0708 D LIVE 0002117706 Pacegenix, Inc. 245 1ST ST, 18TH FLOOR CAMBRIDGE MA MASSACHUSETTS 02142 6126850244 DELAWARE None None Corporation true 2024 Jay Glenn Wohlgemuth c/o Pacegenix, Inc. 245 1st St, 18th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Director Raymond Tabibiazar c/o Pacegenix, Inc. 245 1st St, 18th Floor Cambridge MA MASSACHUSETTS 02142 Director Fredric Neville Eshelman c/o Pacegenix, Inc. 245 1st St, 18th Floor Cambridge MA MASSACHUSETTS 02142 Director Frank Grazzini, II c/o Pacegenix, Inc. 245 1st St, 18th Floor Cambridge MA MASSACHUSETTS 02142 Executive Officer Biotechnology Decline to Disclose 06b false 2026-03-11 false true true true SAFE Convertible Notes false 0 LifeSci Capital, LLC 168404 LifeSci Capital, LLC 168404 1700 Broadway 40th Floor New York NY NEW YORK 10019 CA CALIFORNIA NY NEW YORK NC NORTH CAROLINA TN TENNESSEE true 22533267 22533267 0 false 15 577517 true 0 Includes equity issued as sales compensation per engagement letter dated 2/10/25: 300,000 shares issued to LifeSci at or around 2/10/25 at $0.0001 per share, fair market value of $30, consistent with Rule 501(c) and Form D Item 13 valuation methodology. 600000 true false Pacegenix, Inc. /s/ Jay Glenn Wohlgemuth Jay Glenn Wohlgemuth CEO 2026-03-25